Further exploration employing diverse cell-type-specific promoters for ABCD1 gene delivery could elucidate the predominant cell types implicated in ALD pathology, facilitating the design of more targeted AAV vectors to mitigate the risk of off-target effects, such as neuronal toxicity, and to optimize therapeutic efficacy. This evidence concerns the gene ABCD1 and adrenoleukodystrophy.